We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

134 hedge funds and large institutions have $954M invested in Relmada Therapeutics in 2022 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more funds holding in top 10

Funds holding in top 10: 2 → 7 (+5)

162% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 13

104% more capital invested

Capital invested by funds: $468M → $954M (+$485M)

39% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 33

19% more funds holding

Funds holding: 113 → 134 (+21)

3.48% more ownership

Funds ownership: 82.3% → 85.77% (+3.5%)

41% less call options, than puts

Call options by funds: $117M | Put options by funds: $198M

Holders
134
Holders Change
+21
Holders Change %
+18.58%
% of All Funds
2.31%
Holding in Top 10
7
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+250%
% of All Funds
0.12%
New
34
Increased
46
Reduced
33
Closed
13
Calls
$117M
Puts
$198M
Net Calls
-$81.5M
Net Calls Change
-$85.4M

Top Buyers

1
PA
Perceptive Advisors
New York
+$62.7M
2
BI
BVF Inc
California
+$11.6M
3
NIP
Nicholas Investment Partners
California
+$6.74M
4
GTC
Ghost Tree Capital
New York
+$4.85M
5
SSA
Schonfeld Strategic Advisors
New York
+$4.17M

Top Sellers

1
CAC
Cowen and Company
New York
-$23.6M
2
VA
VR Adviser
New York
-$20.8M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.1M
4
SFM
Sphera Funds Management
Israel
-$7.58M
5
GPP
Great Point Partners
Connecticut
-$5.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
WIA
76
World Investment Advisors
California
$470K – – –
TD Asset Management
77
TD Asset Management
Ontario, Canada
$452K +$13.9K +500 +4%
BC
78
Brookfield Corp
Ontario, Canada
$437K +$327K +11,812 New
CAM
79
Concorde Asset Management
Michigan
$433K +$324K +11,700 New
CG
80
Cutler Group
California
$388K +$217K +7,815 +293%
AI
81
AdvisorShares Investments
Maryland
$387K +$290K +10,458 New
Parallax Volatility Advisers
82
Parallax Volatility Advisers
California
$386K -$1.24M -44,642 -81%
TA
83
Tiedemann Advisors
New York
$377K – – –
IBT
84
International Biotechnology Trust
United Kingdom
$370K +$272K +9,810 +5,163%
AR
85
Advisory Research
Illinois
$357K +$267K +9,647 New
Legal & General Group
86
Legal & General Group
United Kingdom
$329K +$33.9K +1,224 +16%
ACM
87
Altium Capital Management
New York
$315K -$540K -19,500 -70%
US Bancorp
88
US Bancorp
Minnesota
$295K +$203K +7,332 +1,186%
Barclays
89
Barclays
United Kingdom
$263K -$266K -9,598 -57%
Principal Financial Group
90
Principal Financial Group
Iowa
$255K +$190K +6,870 New
Royal Bank of Canada
91
Royal Bank of Canada
Ontario, Canada
$246K +$4.82K +174 +3%
Creative Planning
92
Creative Planning
Kansas
$241K +$180K +6,509 New
I
93
INVST
Indiana
$229K +$187K +6,753 New
VEA
94
Virtus ETF Advisers
New York
$226K +$1.39K +50 +0.8%
FAM
95
Fred Alger Management
New York
$226K +$169K +6,095 New
ASRS
96
Arizona State Retirement System
Arizona
$226K +$169K +6,112 New
UBS Group
97
UBS Group
Switzerland
$225K +$132K +4,756 +358%
Los Angeles Capital Management
98
Los Angeles Capital Management
California
$224K +$168K +6,051 New
SFO
99
Stokes Family Office
Louisiana
$220K +$164K +5,935 New
Janus Henderson Group
100
Janus Henderson Group
United Kingdom
$220K +$164K +5,937 New
2 3
4
5 6

RLMD Hedge Fund Activity: Q3 2022 in Review

134 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2022, worth a combined $954M — up 104% from $468M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new RLMD positions and 13 closed out — a net gain of 21 holders — while 46 added to existing stakes and 33 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $62.7M. The largest seller was Cowen and Company, cutting an estimated $23.6M.

  • 134 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $954M of Relmada Therapeutics stock for Q3 2022, up 104% quarter-over-quarter.
  • 34 funds opened new Relmada Therapeutics positions in Q3 2022 and 13 closed out, a net change of +21 holders.
  • The largest Relmada Therapeutics buyer in Q3 2022 was Perceptive Advisors, an estimated $62.7M added.
  • The largest Relmada Therapeutics seller in Q3 2022 was Cowen and Company, an estimated $23.6M sold.

Based on aggregated 13F filings for Q3 2022.